Alumis Inc. CEO Martin Babler buys $100,732 in company stock

Published 03/04/2025, 23:08
Alumis Inc. CEO Martin Babler buys $100,732 in company stock

In a recent transaction, Martin Babler, President, CEO, and Chairman of Alumis Inc. (NASDAQ:ALMS), acquired 15,650 shares of the company’s common stock. The purchase comes as the stock has shown significant momentum, posting an impressive 82% return over the past week, though it remains 36% lower year-over-year. The shares were purchased at a weighted-average price of $6.44, with prices ranging from $6.18 to $6.95. This acquisition, totaling approximately $100,732, was conducted through a revocable trust for which Babler serves as trustee. Following this transaction, Babler now holds 106,454 shares of Alumis Inc. stock indirectly through the trust. While the company maintains a strong liquidity position with a current ratio of 6.01, InvestingPro analysis indicates rapid cash burn and suggests the stock is currently overvalued. Subscribers can access 8 additional key insights about ALMS’s financial health and market position.

In other recent news, Alumis Inc. reported a net loss of $1.73 per share for the fourth quarter of 2024, which was larger than analysts’ expectations of a $1.39 per share loss. The company’s research and development expenses reached $87.2 million, and general and administrative costs were $11.4 million, both exceeding forecasts. Despite these financial outcomes, H.C. Wainwright maintains a Buy rating on Alumis, although it adjusted the stock’s price target to $15 from $19. Alumis has entered a strategic partnership with Kaken Pharmaceutical (TADAWUL:2070) to develop and commercialize the TYK2 inhibitor, ESK-001, in Japan, potentially earning up to $180 million in payments. Baird reiterated its Outperform rating with a $17 price target, following promising data from Alumis’s Phase 1 study of A-005. Cantor Fitzgerald also maintained an Overweight rating, expressing optimism about ESK-001’s market potential in psoriasis treatment. The anticipated merger with SLRN is expected to bolster Alumis’s financial position, providing capital for ongoing trials. These developments reflect significant strategic moves for Alumis in expanding its therapeutic offerings and strengthening its financial foundation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.